Ondine Biomedical Inc Announces Rising HAIs and Antibiotic Resistance

A recent report by the European Centre for Disease Prevention and Control (ECDC) has shown an increase in healthcare-associated infections (HAIs) and antibiotic usage across European hospitals, according to Ondine Biomedical Inc. The company highlighted that this rise underscores the urgent need for innovative solutions like their Steriwave light-activated antimicrobial technology. This technology is designed to combat pathogens effectively without encouraging antimicrobial resistance (AMR).

The ECDC's findings indicate that 4.3 million patients in the EU/EEA are now affected by HAIs, with a significant proportion of microbes responsible for these infections being resistant to existing antibiotics. Echoing these concerns, ECDC Director Dr. Andrea Ammon emphasized the importance of enhanced infection control and antimicrobial stewardship to protect patient health across Europe.

Ondine Biomedical's Steriwave technology uses a patented method that combines a photosensitizer with red light, targeting harmful pathogens in the nose, a major site for bacteria that can lead to serious infections. This method has already been adopted by hospitals in Canada, the UK, and most recently in Spain, showing no serious side effects and a high efficacy rate in clinical settings.